– CANADA, Vancouver – ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino to its Board of Directors.
“Lauren’s cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the skillset of our Board of Directors. We warmly welcome her to the team and are confident that Lauren’s proven market acumen will support ESSA’s pipeline advancement and collaborations,” said Board Chairman, Richard Glickman.
About Lauren Merendino
Lauren Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios.
“ESSA’s unique program of first-in-class antigens targeting the N-terminal domain of the androgen receptor brings important innovation to the prostate cancer clinical landscape,” said Lauren Merendino. “I am delighted to be appointed to ESSA’s Board of Directors and look forward to leveraging my commercial knowledge and experience in oncological programs to ensure that ESSA’s therapies can be delivered to the patient populations who can benefit the most.”
Ms. Merendino recently joined Day One Biopharmaceuticals as CCO, before which she was CCO at Myovant Sciences. In that role, she led the Commercial organization including sales, marketing, market access, and analytics, to drive the successful launches of two products across three indications within two years. Previously, Ms. Merendino was the VP of Neurological Rare Diseases at Genentech, Inc., where she led a cross-functional team to launch products in the neurological rare disease therapeutic area and collaborate efforts across marketing, medical affairs, and government affairs. Ms. Merendino also held positions of increasing authority at Genentech in the commercial organization across sales, marketing, and strategy, with a focus on oncology. Throughout her career, she has built broad experience in national sales, marketing, as well as commercial strategies for molecules in early development and business development deals.
She earned her B.S. degree in Microbiology from Pennsylvania State University and her M.B.A. in Marketing and Management from New York University.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Source: https://www.essapharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
